Logo image of AGFB.BR

AGFA-GEVAERT NV (AGFB.BR) Stock Fundamental Analysis

EBR:AGFB - Euronext Brussels - BE0003755692 - Common Stock - Currency: EUR

0.897  -0.02 (-2.39%)

Fundamental Rating

2

Overall AGFB gets a fundamental rating of 2 out of 10. We evaluated AGFB against 13 industry peers in the Health Care Technology industry. While AGFB seems to be doing ok healthwise, there are quite some concerns on its profitability. AGFB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGFB had negative earnings in the past year.
In the past year AGFB has reported a negative cash flow from operations.
In the past 5 years AGFB reported 4 times negative net income.
AGFB had a negative operating cash flow in each of the past 5 years.
AGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFAGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

1.2 Ratios

AGFB has a Return On Assets of -6.75%. This is in the lower half of the industry: AGFB underperforms 61.54% of its industry peers.
The Return On Equity of AGFB (-28.88%) is worse than 61.54% of its industry peers.
Industry RankSector Rank
ROA -6.75%
ROE -28.88%
ROIC N/A
ROA(3y)-8.91%
ROA(5y)0.06%
ROE(3y)-32.3%
ROE(5y)1.63%
ROIC(3y)N/A
ROIC(5y)N/A
AGFB.BR Yearly ROA, ROE, ROICAGFB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

AGFB's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 31.11%, AGFB is not doing good in the industry: 69.23% of the companies in the same industry are doing better.
AGFB's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AGFB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.11%
OM growth 3Y-1.64%
OM growth 5Y-16.64%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.88%
AGFB.BR Yearly Profit, Operating, Gross MarginsAGFB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

5

2. Health

2.1 Basic Checks

AGFB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGFB has about the same amout of shares outstanding than it did 1 year ago.
AGFB has less shares outstanding than it did 5 years ago.
AGFB has a worse debt/assets ratio than last year.
AGFB.BR Yearly Shares OutstandingAGFB.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
AGFB.BR Yearly Total Debt VS Total AssetsAGFB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

AGFB has an Altman-Z score of 2.00. This is not the best score and indicates that AGFB is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.00, AGFB is doing good in the industry, outperforming 69.23% of the companies in the same industry.
A Debt/Equity ratio of 0.44 indicates that AGFB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.44, AGFB is in the better half of the industry, outperforming 61.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 2
ROIC/WACCN/A
WACC8.92%
AGFB.BR Yearly LT Debt VS Equity VS FCFAGFB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AGFB has a Current Ratio of 2.00. This indicates that AGFB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AGFB (2.00) is better than 69.23% of its industry peers.
AGFB has a Quick Ratio of 1.26. This is a normal value and indicates that AGFB is financially healthy and should not expect problems in meeting its short term obligations.
AGFB has a better Quick ratio (1.26) than 61.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.26
AGFB.BR Yearly Current Assets VS Current LiabilitesAGFB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.27% over the past year.
AGFB shows a decrease in Revenue. In the last year, the revenue decreased by -1.04%.
Measured over the past years, AGFB shows a very negative growth in Revenue. The Revenue has been decreasing by -10.44% on average per year.
EPS 1Y (TTM)11.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1911.52%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y-13.53%
Revenue growth 5Y-10.44%
Sales Q2Q%3.83%

3.2 Future

Based on estimates for the next years, AGFB will show a very strong growth in Earnings Per Share. The EPS will grow by 54.87% on average per year.
Based on estimates for the next years, AGFB will show a small growth in Revenue. The Revenue will grow by 2.94% on average per year.
EPS Next Y112.7%
EPS Next 2Y71.82%
EPS Next 3Y54.87%
EPS Next 5YN/A
Revenue Next Year2.32%
Revenue Next 2Y2.46%
Revenue Next 3Y2.94%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGFB.BR Yearly Revenue VS EstimatesAGFB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
AGFB.BR Yearly EPS VS EstimatesAGFB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGFB. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 65.97, which means the current valuation is very expensive for AGFB.
The rest of the industry has a similar Price/Forward Earnings ratio as AGFB.
AGFB is valuated expensively when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 65.97
AGFB.BR Price Earnings VS Forward Price EarningsAGFB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGFB.BR Per share dataAGFB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AGFB's earnings are expected to grow with 54.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y71.82%
EPS Next 3Y54.87%

More info and screens

0

5. Dividend

5.1 Amount

AGFB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGFA-GEVAERT NV

EBR:AGFB (4/29/2025, 7:00:00 PM)

0.897

-0.02 (-2.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-14 2025-05-14
Inst Owners52.83%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap138.87M
Analysts75.56
Price Target1.19 (32.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-5.11%
Max Revenue beat(2)-1.72%
Revenue beat(4)0
Avg Revenue beat(4)-5.72%
Min Revenue beat(4)-11.52%
Max Revenue beat(4)-1.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.71%
PT rev (3m)-0.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)188.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.57%
Revenue NY rev (3m)-1.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 65.97
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 1.8
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)0.01
Fwd EY1.52%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS7.35
BVpS2.08
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.75%
ROE -28.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.11%
FCFM N/A
ROA(3y)-8.91%
ROA(5y)0.06%
ROE(3y)-32.3%
ROE(5y)1.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.64%
OM growth 5Y-16.64%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.88%
F-Score2
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.14%
Cap/Sales 3.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.26
Altman-Z 2
F-Score2
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)78.36%
Cap/Depr(5y)64.97%
Cap/Sales(3y)3.26%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1911.52%
EPS Next Y112.7%
EPS Next 2Y71.82%
EPS Next 3Y54.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y-13.53%
Revenue growth 5Y-10.44%
Sales Q2Q%3.83%
Revenue Next Year2.32%
Revenue Next 2Y2.46%
Revenue Next 3Y2.94%
Revenue Next 5YN/A
EBIT growth 1Y-444.44%
EBIT growth 3Y-14.94%
EBIT growth 5Y-25.35%
EBIT Next Year235.46%
EBIT Next 3Y66.5%
EBIT Next 5YN/A
FCF growth 1Y23.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.67%
OCF growth 3YN/A
OCF growth 5YN/A